In a landmark development for the field of hematology, researchers from the Dana-Farber Cancer Institute have unveiled results from the Phase II ImmunoPRISM trial, signaling a potential paradigm shift in the management of high-risk smoldering multiple myeloma (SMM). The study, presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, provides the first randomized evidence that early intervention with a BCMA-targeted bispecific antibody—teclistamab—significantly outperforms current standard-of-care therapies.
For patients diagnosed with high-risk SMM, the clinical horizon has historically been defined by a precarious "watch and wait" approach or, more recently, delayed intervention with traditional agents. The ImmunoPRISM trial suggests that by deploying advanced immunotherapy at the precursor stage, clinicians may be able to fundamentally alter the disease’s trajectory, achieving deep, durable remissions long before the onset of symptomatic, life-altering cancer.
Main Facts: The ImmunoPRISM Breakthrough
The ImmunoPRISM trial is a pioneering, first-of-its-kind randomized study designed to evaluate the efficacy of teclistamab in patients identified as having high-risk smoldering multiple myeloma. High-risk SMM is characterized by a significant probability of progression to active, symptomatic multiple myeloma—a condition marked by bone damage, kidney failure, and anemia. Approximately 50% of patients categorized as high-risk will progress to active disease within two years.
Teclistamab, a bispecific antibody that redirects T cells to target B-cell maturation antigen (BCMA) on myeloma cells, has previously demonstrated efficacy in the relapsed/refractory setting. However, its application in the earlier smoldering stage represents a strategic shift toward "interception."
Key Trial Highlights:
- Superiority: Teclistamab demonstrated significantly higher response rates compared to the combination of lenalidomide and dexamethasone.
- Depth of Response: 75.6% of patients treated with teclistamab achieved a complete response (CR), a feat not matched by any patient in the control group.
- Minimal Residual Disease (MRD): Among evaluable patients, 82% achieved MRD-negativity with teclistamab, indicating an absence of detectable cancer cells at a molecular level.
- Progression-Free Survival (PFS): The data indicated a marked improvement in keeping the disease at bay, with significantly fewer patients progressing compared to those on standard combination therapy.
Chronology of the Clinical Investigation
The road to the ImmunoPRISM findings began with the identification of a clinical gap: the need for a more potent intervention in the SMM stage that could leverage the "immune fitness" of patients before their disease burden—and their immune systems—became compromised by multiple lines of subsequent therapy.
Pre-Trial Rationale
Historically, the standard of care for SMM was observation. While trials such as those utilizing lenalidomide plus dexamethasone showed the potential to delay progression, they were often limited by long-term toxicity or the eventual emergence of resistant clones. Researchers at Dana-Farber, led by Dr. Omar Nadeem and Dr. Irene Ghobrial, hypothesized that the potent immune-engaging mechanism of bispecific antibodies could be more effective if introduced when the tumor burden is lower and the patient’s T-cell function remains relatively intact.
Enrollment and Methodology
The trial enrolled 59 patients who met strict, established risk criteria for high-risk smoldering multiple myeloma. Participants were randomized into two cohorts: 45 patients received teclistamab, while 14 were assigned to the lenalidomide-dexamethasone combination.
The EHA 2026 Presentation
The findings were unveiled as a late-breaking abstract at the EHA Congress in Stockholm (June 11–14, 2026). Dr. Omar Nadeem, the Medical Director of the Center of Early Detection and Interception of Blood Cancers at Dana-Farber, presented the data, which immediately drew international attention for the stark contrast in outcomes between the two study arms.
Supporting Data: Quantitative Evidence of Efficacy
The statistical divergence between the teclistamab and the standard-of-care group provides a robust argument for the efficacy of early immunologic intervention.
Response Rates and Remission Depth
The disparity in complete response (CR) rates is arguably the most compelling metric from the trial. While 75.6% of the teclistamab cohort achieved CR, the lenalidomide-dexamethasone group reported zero patients reaching this milestone. Furthermore, when looking at the category of "very good partial response" (VGPR) or better, the teclistamab group saw an 87% success rate compared to only 14% in the control group.
MRD-Negativity: The New Gold Standard
Minimal Residual Disease (MRD) status is currently the most sensitive metric for predicting long-term outcomes in myeloma. The fact that 82% of evaluable patients on teclistamab achieved MRD-negativity—with these responses remaining durable at the time of data cutoff—suggests that the treatment is not merely suppressing the cancer, but potentially eliminating it at a level that could translate into long-term, treatment-free survival.
Progression-Free Survival (PFS)
The survival data paints a clear picture of the clinical benefit. After a median follow-up of 23.4 months, only 7% of patients in the teclistamab arm had experienced disease progression. In contrast, 36% of those receiving the combination therapy had progressed. Estimates suggest a 92% two-year survival and disease-free rate for the teclistamab group, compared to 51% for the control group.
Safety and Tolerability Profile
A critical concern with T-cell redirection therapies is the side-effect profile, particularly cytokine release syndrome (CRS) and neurotoxicity. In the ImmunoPRISM trial, 71% of patients experienced CRS; however, all reported cases were classified as low-grade, suggesting that the risk can be managed effectively in this patient population. Notably, no neurological toxicities were observed, and the incidence of high-grade infections was lower than that seen in trials involving heavily pre-treated, relapsed/refractory patients.
Official Responses and Clinical Perspectives
The medical community has reacted with cautious optimism, viewing these results as a validation of the "interception" model of cancer treatment.
Dr. Omar Nadeem underscored the significance of these findings in his presentation, stating: "These are striking results because this is the first randomized study to show that a BCMA-targeted bispecific therapy can outperform a lenalidomide-based approach in high-risk smoldering myeloma. We saw rapid, deep responses… these findings suggest that treating patients earlier—before they develop symptomatic multiple myeloma—may meaningfully change the trajectory of the disease."
Echoing this sentiment, Dr. Irene Ghobrial, Director of the Center for Early Detection and Interception of Blood Cancers at Dana-Farber, highlighted the biological rationale: "By harnessing the immune system before the onset of symptomatic disease, teclistamab may leverage preserved immune fitness and lower disease burden to achieve deeper, more durable disease control."
Implications for Future Care and Research
The success of the ImmunoPRISM trial raises fundamental questions about the future of myeloma treatment. If teclistamab can move from the relapsed/refractory setting to the smoldering stage, it opens the door for a new era of proactive hematology.
The Shift Toward Interception
The traditional model of oncology focuses on treating disease once it has reached a symptomatic threshold. The ImmunoPRISM trial demonstrates that by identifying patients at high risk and intervening with highly targeted immunotherapy, clinicians can prevent the morbidity associated with bone fractures, kidney failure, and other hallmark complications of active myeloma.
Rethinking Standard of Care
The results present a challenge to the existing standard of care. If a therapy can deliver a 75% complete response rate in a precursor state, the standard "watch and wait" approach may become increasingly difficult to justify for high-risk patients. However, further long-term studies will be necessary to confirm the durability of these remissions and to fully understand the long-term safety of extended bispecific antibody administration in a population that would otherwise be asymptomatic for a period.
Future Research Directions
The Dana-Farber team’s success with the ImmunoPRISM trial serves as a blueprint for future studies. Researchers are likely to explore:
- Fixed-Duration Therapy: Can patients achieve deep, durable remissions with a finite course of teclistamab, thereby minimizing long-term exposure and cost?
- Combination Strategies: Could teclistamab be combined with other novel agents to further improve the depth of response or the proportion of patients reaching MRD-negativity?
- Refined Risk Stratification: As treatments become more effective, the ability to accurately identify which "smoldering" patients truly require this level of intervention becomes paramount.
Conclusion
The ImmunoPRISM trial is more than just a successful Phase II study; it is a proof-of-concept for the power of immune interception in blood cancers. By demonstrating that the depth and quality of response to BCMA-targeted therapy are superior in the smoldering setting compared to later stages of the disease, the Dana-Farber researchers have provided a compelling case for shifting the treatment paradigm. For patients living with the anxiety of high-risk smoldering multiple myeloma, the results offer something that was once considered a luxury in this field: the tangible hope of a future where active, symptomatic cancer may be avoided entirely.
About the Author
